Long‐term prognosis of focal segmental glomerulosclerosis treated with therapeutic low‐density lipoprotein‐apheresis in patients with severe kidney dysfunction and proteinuria

Long‐term prognosis of focal segmental glomerulosclerosis treated with therapeutic low‐density lipoprotein‐apheresis in patients with severe kidney dysfunction and proteinuria

Abstract Background The prognosis of focal segmental glomerulosclerosis patients with nephrotic syndrome is estimated to be 10%–20% in 5 years and 30%–50% in 10 years, leading to end‐stage kidney disease. The response rate with steroid therapy is 40%–60%. Therapeutic low‐density lipoprotein‐apheresi...

Full description

Bibliographic Details
Main Authors: Shinji Kitajima, Megumi Osima, Hisayuki Ogura, Shiori Nakagawa, Yuta Yamamura, Taito Miyake, Taro Miyagawa, Tadashi Toyama, Akinori Hara, Norihiko Sakai, Miho Shimizu, Takashi Wada, Yasunori Iwata
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Rheumatology & Autoimmunity
Subjects:
apheresis
end‐stage kidney disease
focal segmental glomerulosclerosis
LDL
prognosis
Online Access:https://doi.org/10.1002/rai2.12068

Internet

https://doi.org/10.1002/rai2.12068

Similar Items